Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Dold

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Evidence-Based Mental Health|April 10, 2014
Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspectiveMarkus Dold, Stefan Leucht
International Journal of Psychiatry in Clinical Practice|November 17, 2016
Evidence-based pharmacotherapy of treatment-resistant unipolar depressionMarkus Dold, Siegfried Kasper
Acta Psychiatrica Scandinavica|December 14, 2020
Dose-response relationship of selective serotonin reuptake inhibitorsMarkus Dold, Siegfried Kasper
Evidence-Based Mental Health|July 1, 2015
Increasing placebo response in antipsychotic trials: a clinical perspectiveMarkus Dold, Siegfried Kasper
Neuropsychiatrie : Klinik, Diagnostik, Therapie Und Rehabilitation : Organ Der Gesellschaft Osterreichischer Nervenarzte Und Psychiater|November 14, 2009
[Neuroimaging the various symptom dimensions of obsessive-compulsive disorder]Markus Dold, Martin Aigner
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 27, 2015
Factors contributing to the increasing placebo response in antidepressant trialsSiegfried Kasper, Markus Dold
The International Journal of Neuropsychopharmacology|June 23, 2020
Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic TreatmentMarkus Dold, Lucie Bartova, Siegfried Kasper
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 23, 2013
Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trialsMarkus Dold, Chunbo Li, Donna Gillies, et al.
The International Journal of Neuropsychopharmacology|May 6, 2015
Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled TrialsMarkus Dold, Martin Aigner, Rupert Lanzenberger, et al.
The International Journal of Neuropsychopharmacology|August 31, 2012
Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trialsMarkus Dold, Martin Aigner, Rupert Lanzenberger, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Evidence-Based Mental Health|April 10, 2014
Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspectiveMarkus Dold, Stefan Leucht
International Journal of Psychiatry in Clinical Practice|November 17, 2016
Evidence-based pharmacotherapy of treatment-resistant unipolar depressionMarkus Dold, Siegfried Kasper
Acta Psychiatrica Scandinavica|December 14, 2020
Dose-response relationship of selective serotonin reuptake inhibitorsMarkus Dold, Siegfried Kasper
Evidence-Based Mental Health|July 1, 2015
Increasing placebo response in antipsychotic trials: a clinical perspectiveMarkus Dold, Siegfried Kasper
Neuropsychiatrie : Klinik, Diagnostik, Therapie Und Rehabilitation : Organ Der Gesellschaft Osterreichischer Nervenarzte Und Psychiater|November 14, 2009
[Neuroimaging the various symptom dimensions of obsessive-compulsive disorder]Markus Dold, Martin Aigner
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 27, 2015
Factors contributing to the increasing placebo response in antidepressant trialsSiegfried Kasper, Markus Dold
The International Journal of Neuropsychopharmacology|June 23, 2020
Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic TreatmentMarkus Dold, Lucie Bartova, Siegfried Kasper
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 23, 2013
Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trialsMarkus Dold, Chunbo Li, Donna Gillies, et al.
The International Journal of Neuropsychopharmacology|May 6, 2015
Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled TrialsMarkus Dold, Martin Aigner, Rupert Lanzenberger, et al.
The International Journal of Neuropsychopharmacology|August 31, 2012
Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trialsMarkus Dold, Martin Aigner, Rupert Lanzenberger, et al.
Pageof 7